Oct. 3 at 2:38 AM
$KZIA This announcement & news of circulating cancer cell reduction, serve as micro steps to mature the preclinic data. Success here will void the worth of other cancer drugs & bring dramatic change to cancer treatment. For the first time, the Pi3k ARK /mTOR drug class, & the broader properties of paxalisib, will succeed where EMT specific, targeted drugs have failed. QUOTE When tumor cells undergo epithelial-to-mesenchymal transition (EMT), they shed their structured, anchored characteristics and become mobile invaders capable of spreading throughout the body. The pharmaceutical industry has taken notice. Major players are investing in therapies designed to disrupt EMT pathways, recognizing that controlling this transition could fundamentally alter cancer outcomes. The science is compelling: by preventing cancer cells from acquiring mesenchymal traits, therapies could theoretically halt metastasis before it begins while simultaneously re-sensitizing tumors to existing treatments.
